Interleukin-2 Immunotherapy Followed by Resection of Residual Renal Cell Carcinoma
Author:
Affiliation:
1. From the Division of Urology and Department of Surgery, MetroHealth Medical Center, Case Western Reserve University, Cleveland, Ohio
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Urology
Reference23 articles.
1. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients;Rosenberg;Ann. Surg.,1989
2. Metastatic renal cancer treated with interleukin-2 and lympnokine-activated killer cells. A phase II clinical trial;Fisher;Ann. Intern. Med.,1988
3. A phase II clinical trial of adoptive immunotherapy for advanced renal cell carcinoma using mitogen-activated autologous leukocytes and continuous infusion interleukin-2;Wang;J. Clin. Oncol.,1989
4. Phase II trial of high-dose intermittent interleukin-2 in metastatic renal cell carcinoma: a Southwest Oncology Group study;Bukowski;J. Natl. Cancer Inst.,1990
5. Adoptive cellular therapy of renal carcinoma;West,1989
Cited by 65 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Reply to Michael Staehler, Dena Battle, Axel Bex, Hans Hammers, and Daniel George's Letter to the Editor re: Arnaud Méjean, Alain Ravaud, Simon Thezenas, et al. Sunitinib Alone or After Nephrectomy in Metastatic Renal-cell Carcinoma. Eur Urol 2018;74:842–3;European Urology;2019-03
2. Current management and future perspectives of metastatic renal cell carcinoma;International Journal of Urology;2014-05-27
3. Nierenzellkarzinom;Uroonkologie;2014
4. Consolidative surgery after targeted therapy for renal cell carcinoma;Urologic Oncology: Seminars and Original Investigations;2013-08
5. Integration of Surgery in Metastatic Renal Cancer;Renal Cell Carcinoma;2012-08-07
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3